SCHEMBL6197162

SCHEMBL6197162

COC(=O)c1ccc2ccc(CN(C=O)OC(C)(C)C)cc2c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LCK P06239 1/20 0.39
PTPN11 Q06124 1/20 0.38
LOXL2 Q9Y4K0 2/20 0.38
POLB P06746 1/20 0.37
NR1H4 Q96RI1 5/20 0.37
CA1 P00915 2/20 0.36
CA2 P00918 2/20 0.36
MAPK8 P45983 1/20 0.35
MAPK10 P53779 1/20 0.35
ALDH1A1 P00352 1/20 0.35
CA12 O43570 1/20 0.35
CA7 P43166 1/20 0.35
XDH P47989 1/20 0.35
CA9 Q16790 1/20 0.35
CA14 Q9ULX7 1/20 0.35
CYP4A11 Q02928 1/20 0.35
ALOX15 P16050 1/20 0.35
HTT P42858 1/20 0.35
HSP90AA1 P07900 1/20 0.35
MEN1 O00255 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5544978 0.96 PTPN11 (0.41) LCKPTPN11LOXL2POLBNR1H4
SCHEMBL5548141 0.86 LOXL2 (0.47) LOXL2CA1CA2ALDH1A1CA12
SCHEMBL5548483 0.84 LOXL2 (0.52) LOXL2ALDH1A1CYP4A11MEN1KMT2A
SCHEMBL3149487 0.73 CYP4A11 (0.50) LCKPTPN11LOXL2POLBCA1
SCHEMBL19829368 0.73 PTPN11 (0.47) LCKPTPN11LOXL2POLBCA1
SCHEMBL709231 0.72 LCK (0.62) LCKPTPN11CA1CA2ALDH1A1
SCHEMBL3145033 0.72 LCK (0.49) LCKPTPN11LOXL2POLBCA1
SCHEMBL6772434 0.72 HTR7 (0.36) ALDH1A1
SCHEMBL6197159 0.72 NAMPT (0.46) LCKPOLBALDH1A1
SCHEMBL5604152 0.71 MEP1B (0.46) NR1H4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1031563-B1 SULFONYL DERIVATIVES DAIICHI SEIYAKU CO (JP) 2005-12-28 EP disclosed
US-6747023-B1 INHIBITORS FOR ACTIVATED COAGULATION FACTOR X, COAGULATION SUPPRESSORS DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-06-08 US disclosed
US-20040082611-A1 Anticoagulants; brain disorders; respiratory system disorders; side effect reduction DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-04-29 US disclosed
US-20030232808-A1 Sulfonyl derivatives DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2003-12-18 US disclosed
US-6525042-B1 Inhibits an activated coagulation factor FXa; anticoagulant, antithrombotic DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2003-02-25 US disclosed
EP-1104754-A1 NOVEL SULFONYL DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2001-06-06 EP disclosed
EP-1031563-A1 SULFONYL DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2000-08-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040082611-A1 Anticoagulants; brain disorders; respiratory system disorders; side effect reduction F2, CYC1, SULT2A1 LCK 4575/4885PTPN11 2617/4885LOXL2 2044/4885
US-20030232808-A1 Sulfonyl derivatives SULT1E1, SULT2A1, SULT1A1 LCK 3878/4885PTPN11 991/4885LOXL2 957/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.